Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations
Further Publications Urology
Related content
Uro-Oncology
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Prostate.
Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH
doi: 10.1002/pros.23954.
Uro-Oncology
Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer
Prostate.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M
doi: 10.1002/pros.23919.
Uro-Oncology
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
doi: 10.1016/j.eururo.2018.11.016.
Uro-Oncology
Germline BLM mutations and metastatic prostate cancer
Prostate.
Ledet EM, Antonarakis ES, Isaacs WB, Lotan TL, Pritchard C, Sartor AO
doi: 10.1002/pros.23924.
Uro-Oncology
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer
Eur Urol.
Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA,
Antonarakis ES
doi: 10.1016/j.eururo.
Uro-OncologyFurther Publications Urology
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer
Eur Urol
Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ
doi: 10.1016/j.eururo.2021.09.030
Uro-Oncology
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer Prostatic Dis
Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A
doi: 10.1038/s41391-021-00436-y
Uro-Oncology
Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer
Cancer.
Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardino PT, Lin Y, Kim IY, Lu-Yao GL
doi: 10.1002/cncr.31726.
COMMENTED
Uro-Oncology
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
★ 3
Recommended by
Alexander Meisel, Faculty Member
Eur Urol.
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators.
doi: 10.1016/j.eururo.2019.09.019.